These pre-clinical observations on oxidoreductase-containing epitopes and their elicitation of CD4+ T cells capable of specifically eliminating APCs presenting the nominal peptide opens a door to a novel therapeutic strategy in immune disease and leads to hypothesize that any class II-restricted T cell epitope can be modified by addition of a oxidoreductase motif in order to induce specific CD4+ T cells with apoptosis-inducing properties and thus overcome any unwanted class II-restricted immune response. Here, CD4 is linked to immune system disorder.